Poly Medicure Ltd.
Fundamentals
- Market cap
- ₹16,734 cr
- P/E
- 51.95×
- ROE
- 12.24%
- Debt / equity
- 0.06
- Div yield
- 0.21%
- 52-week range
- 1184.00 — 2318.35
Company snapshot
Poly Medicure Ltd.
Pharmaceuticals
₹13,467 cr
P/E 41.80×
Latest quarter · Mar 2026
Sales₹535 cr
Net profit₹63 cr
Op. margin+20.6%
EPS₹6.54
Strength & growth
Debt / equity0.06×
Current ratio4.38×
Sales CAGR+16.8%
EPS CAGR+18.5%
The timeline — 4 notes on Poly Medicure Ltd.
May 2026
- 25 May 26 · 7:58 PM IST Brief Brief · Earnings · Mid cap
Poly Medicure's Q4 profit drops 29% as acquisition costs bite
Consolidated net profit fell 29% in Q4, with standalone down 7%. The results confirm softer trends already flagged in an earlier concall.
- 25 May 26 · 6:16 PM IST Brief Brief · Concalls · Mid cap
Poly Medicure walks back PendraCare revenue, renal growth targets
The post-results call corrected a key metric downward and cut a growth forecast, while acquisitions weighed on margins.
- 25 May 26 · 4:42 PM IST Brief Brief · Earnings · Mid cap
Poly Medicure's Q4 profit drops 7% standalone, 29% consolidated on acquisition costs
Standalone net profit slipped to ₹8,062 lacs while consolidated profit took a 29% hit from deal-related expenses. Full-year standalone profit rose just 1.4%.
- 25 May 26 · 3:23 PM IST Brief Brief · Earnings · Mid cap
Poly Medicure profit slips in Q4, hit by acquisition costs
Standalone net profit fell 7% even as revenue grew. On a consolidated basis, profit dropped 29% as acquisition-related expenses weighed.